New York, New York (PRWEB) March 01, 2013
Federal regulators are seeking data regarding the da Vinci Surgical System, amid an increase in reports of da Vinci Surgery robot complications, Bernstein Liebhard LLP reports. According to Bloomberg.com, the U.S. Food & Drug Administration (FDA) has sent a letter to hospitals participating in an agency-run product safety network asking them to provide information about adverse events related to the da Vinci Surgical System, a robotic surgery platform marketed by Intuitive Surgical. Surgeons at those hospitals were asked to list possible da Vinci surgery robot complications they may have seen with the machines, as well as which surgeries the robots might be most and least suited for. They were also asked to discuss their training on the da Vinci Surgical System.*
“We have heard from numerous individuals who allegedly suffered serious complications in da Vinci robot procedures. We are pleased to hear that the FDA is looking into this issue,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free da Vinci surgical robot lawsuit consultations to individuals who suffered serious complications that may be related to the da Vinci Surgical System.
Da Vinci Surgical Robot Lawsuit
According to Bloomberg.com, the da Vinci robot has been on the market since 2000, and was used last year in some 500,000 procedures, including hysterectomies, gall bladder removal, prostate removal, heart surgeries, and thyroid procedures. The da Vinci surgery complication reports sent to the FDA include many that involve gynecological surgeries. According to Bloomberg.com, injuries detailed in the reports include damage to ureters and bowels, instances when instruments broke off from the robot and fell into patients, and burns to various organs or vessels.
According to Bernstein Liebhard LLP, a study published earlier this month in the Journal of the American Medical Association (JAMA) reported that robot-assisted surgery is increasingly being used in minimally-invasive hysterectomy. According to the JAMA article, robotic surgery was used in just 0.5 percent of operations studied in 2007, but grew to almost 10 percent by early 2010. The rate of complications for both robotic procedures and traditional laparoscopies was roughly the same. However, the costs for robotic hysterectomies totaled nearly $9,000, versus about $3,000 for the least expensive method, the study found. “Our study indicates that, while robotic assistance was associated with increased use of minimally invasive surgery for hysterectomy, when compared with laparoscopic hysterectomy, the robotic procedure offers little short-term benefit and is accompanied by significantly higher costs,” the authors of the study wrote.**
Patients who suffered surgical burns, organ damage, or other serious injuries allegedly due to the da Vinci Surgical System may be entitled to file a da Vinci robot lawsuit to obtain compensation for medical expenses, lost wages, pain and suffering, and more. A wealth of information regarding da Vinci robot legal claims is available at Bernstein Liebhard LLP’s da Vinci surgical robot lawsuit website. For additional information, contact a lawyer at Bernstein Liebhard LLP today by calling (877) 779-1414.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP